Patents by Inventor Shimpei Kawakami
Shimpei Kawakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10426784Abstract: Compounds of formula (I) defined herein are useful as a dopamine D1 receptor positive allosteric modulators (D1 PAM) and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like.Type: GrantFiled: June 17, 2016Date of Patent: October 1, 2019Assignee: Astellas Pharma Inc.Inventors: Shimpei Kawakami, Tomoyoshi Imaizumi, Naoyuki Masuda, Shigeki Kunikawa, Masataka Morita, Junko Yarimizu
-
Publication number: 20180185383Abstract: [Problem] Provided is a compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Means for Solution] The present inventors have studied a compound which has a positive allosteric modulating action (PAM action) on a dopamine D1 receptor and which can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like. Thus, they have found that the imidazodiazepine compound of the present invention has a PAM action on a dopamine D1 receptor, and thereby completed the present invention.Type: ApplicationFiled: June 17, 2016Publication date: July 5, 2018Applicant: Astellas Pharma Inc.Inventors: Shimpei KAWAKAMI, Tomoyoshi IMAIZUMI, Naoyuki MASUDA, Shigeki KUNIKAWA, Masataka MORITA, Junko YARIMIZU
-
Patent number: 9708307Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: October 28, 2014Date of Patent: July 18, 2017Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Patent number: 9670219Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.Type: GrantFiled: September 7, 2016Date of Patent: June 6, 2017Assignee: Astellas Pharma Inc.Inventors: Yohei Koganemaru, Satoshi Miyamoto, Shinya Nagashima, Akio Kamikawa, Koichi Yonezawa, Yuka Koizumi, Satoshi Aoki, Takashi Ogiyama, Shimpei Kawakami, Shigeki Kunikawa, Ryo Sato, Junichi Shishikura, Shuichirou Kakimoto, Hiroshi Yamada, Keisuke Tamaki
-
Publication number: 20170050973Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.Type: ApplicationFiled: September 7, 2016Publication date: February 23, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Yohei KOGANEMARU, Satoshi MIYAMOTO, Shinya NAGASHIMA, Akio KAMIKAWA, Koichi YONEZAWA, Yuka KOIZUMI, Satoshi AOKI, Takashi OGIYAMA, Shimpei KAWAKAMI, Shigeki KUNIKAWA, Ryo SATO, Junichi SHISHIKURA, Shuichirou KAKIMOTO, Hiroshi YAMADA, Keisuke TAMAKI
-
Patent number: 9266840Abstract: To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11?-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11?-HSD1.Type: GrantFiled: October 17, 2012Date of Patent: February 23, 2016Assignee: ASTELLAS PHARMA INC.Inventors: Shimpei Kawakami, Minoru Sakurai, Noriyuki Kawano, Takayuki Suzuki, Nobuyuki Shiraishi, Wataru Hamaguchi, Ryuichi Sekioka, Hiroyuki Moritomo, Ayako Moritomo
-
Publication number: 20150045402Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko TOBE, Shimpei KAWAKAMI, Hiroyuki MORITOMO, Makoto OHMIYA
-
Patent number: 8937087Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: April 18, 2014Date of Patent: January 20, 2015Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20140315963Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20140249151Abstract: [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11?-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11?-HSD1.Type: ApplicationFiled: October 17, 2012Publication date: September 4, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Shimpei Kawakami, Minoru Sakurai, Noriyuki Kawano, Takayuki Suzuki, Nobuyuki Shiraishi, Wataru Hamaguchi, Ryuichi Sekioka, Hiroyuki Moritomo, Ayako Motitomo
-
Patent number: 8497286Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: GrantFiled: September 14, 2012Date of Patent: July 30, 2013Assignee: Novartis AGInventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Patent number: 8383650Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: GrantFiled: June 25, 2008Date of Patent: February 26, 2013Assignee: Novartis AGInventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Publication number: 20130005770Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: ApplicationFiled: September 14, 2012Publication date: January 3, 2013Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Patent number: 8163773Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.Type: GrantFiled: July 10, 2006Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Werner Breitenstein, Claus Erhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Keiichi Masuya, Kazuhide Konishi, Fumiaki Yokokawa, Takanori Kanazawa, Edgar Jacoby, Andreas Marzinzik, Philipp Grosche, Shimpei Kawakami
-
Patent number: 8129411Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 are as defined in the specification.Type: GrantFiled: December 28, 2006Date of Patent: March 6, 2012Assignee: Novartis AGInventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa
-
Publication number: 20090233920Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.Type: ApplicationFiled: July 10, 2006Publication date: September 17, 2009Inventors: Werner Breitenstein, Claus Erhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Keiichi Masuya, Kazuhide Konishi, Fumiaki Yokokawa, Takanori Kanazawa, Edgar Jacoby, Andreas Marzinzik, Philipp Grosche, Shimpei Kawakami
-
Publication number: 20090192148Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 areas defined in the specification.Type: ApplicationFiled: December 28, 2006Publication date: July 30, 2009Inventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa
-
Publication number: 20080319018Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: ApplicationFiled: June 25, 2008Publication date: December 25, 2008Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuku Hitomi, Atsushi Toyao